Oral Insulin – Harnessing the Natural Physiology of Glucose Control in the Body

Main Article Content

Roger R. C. New, PhD

Abstract

The aim of this paper is to highlight the ideal prerequisites for an oral insulin formulation to exert its maximal effect, by delivering insulin via the portal vein directly to the liver. A description is provided of the resulting differences in the way in which oral and injected insulins act, in order to treat type 2 diabetes. Key among these differences is the ability of the liver to control its activity in accord with the glucose concentration in the bloodstream, as a result of insulin entering the liver via the portal vein, and stimulating generation of glucokinase. The advantages this confers on multiple aspects of treatment of patients (safety, dosing, reproducibility etc) are outlined in detail. Separately, the way in which insulin, administered via the upper intestine, may overcome insulin resistance is discussed. Finally, a case is made for oral insulin to be employed for treatment of type 1 diabetes, gestational diabetes, and for co-administration with certain other anti-diabetes agents.

Article Details

How to Cite
NEW, Roger R. C.. Oral Insulin – Harnessing the Natural Physiology of Glucose Control in the Body. Medical Research Archives, [S.l.], v. 13, n. 1, jan. 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6180>. Date accessed: 10 feb. 2025. doi: https://doi.org/10.18103/mra.v13i1.6180.
Section
Research Articles

References

1. Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, Schatz D, Vargas, A, Rogers D, Schwartz S, Malone J, Krischer J, Maclaren NK. Oral Insulin Therapy to Prevent Progression of Immune-Mediated (Type 1) Diabetes. Ann. N.Y. Acad. Sci. 2004; 1029: 260–277.
2. The Diabetes Prevention Trial – Type 1. Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes. Diabetes Care. 2005;28:5 1068-1076.
3. New RRC, Bogus M, Travers GN, Hahn U, Vaiceliunaite A, Burnet M, Wang JH and Wen H. Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery. Front. Drug Deliv. 2024;4:1456654. doi: 10.3389/fddev.2024.1456654.
4. Massa ML, Gagliardino JJ, Francini F. Liver Glucokinase: An Overview on the Regulatory Mechanisms of its Activity. IUBMB Life. 2011;63(1): 1–6.
5. Kaminski MT, Schultz J, Waterstradt R, Tiedge M, Lenzen S, Baltrusch S. Glucose-induced dissociation of glucokinase from its regulatory protein in the nucleus of hepatocytes prior to nuclear export. Biochimica et Biophysica Acta. 2014;1843:554–564.
6. Matschinsky FM, Wilson DF. The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans. Front. Physiol. 2019;10:148.doi: 10.3389/fphys.2019.00148.
7. Luzio SD, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens DR. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes Diabetes, Obesity and Metabolism. 2009 doi: 10.1111/j.1463-1326.2009.01146.x.
8. Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J. 2021;45:285-311. doi.org/10.4093/dmj.2020.0250.
9. Edgerton DS, Scott M, Farmer B, Williams PE, Madsen P, Kjeldsen T, Brand CL, Fledelius C, Nishimura N, Cherrington AD. Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery. JCI Insight. 2019; 5: e126974.
10. Kolb H, Kempf K, Röhling M, Martin S. Insulin: too much of a good thing is bad. BMC Medicine. 2020;18:224. doi.org/10.1186/s12916-020-01688-6.
11. New RRC, Ramanujam S, Chaudhari V, Bogus M, Travers GN. Namjoshi G. Safety and Efficacy of an Oral Insulin (Capsulin) in Patients with Early-Stage Type 2 Diabetes: A Dose-Ranging Phase IIb Study. Diabetes Obes Metab. 2022;1–8.
12. Lebovitz HE, Fleming A, Cherrington AD, Joshi S, Athalye SN, Loganathan S, Vishweswaramurthy A, Panda J, Marwah A. Efficacy and Safety of Tregopil, a Novel, Ultra-Rapid Acting Oral Prandial Insulin Analog, as Part of a Basal-Bolus Regimen in Type 2 Diabetes: A Randomized, Active Controlled Phase 2/3 Study. Expert Opinion on Pharmacotherapy. 2022; doi: 10.1080/14656566.2022.2141569.
13. Eldor R, Francis BH, Fleming A, Neutel J, Homer K, Kidron M, Rosenstock J. Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study. Diabetes, Obesity and Metabolism 2022 doi.org/10.1111/dom.14901
14. Weng JP, Li YB, Xu W, Shi LX, Zhang Q, Zhu DL, Hu Y, Zhou ZG, Yan X, Tian HM, Ran XW, Luo ZJ, Xian J, Yan L, Li FP, Zeng LY, Chen YM, Yang LY, Yan SJ, Liu J, Li M, Fu ZZ, Cheng H. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371: 1753–60.
15. Meneghini LF. Early Insulin Treatment in Type 2 Diabetes: What are the pros? Diabetes Care. 2009;32:S226-269.
16. Owens DR. Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 Diabetes. Diabetes Technology and Therapeutics. 2013; 15: 776-785 DOI: 10.1089/dia.2013.0081
17. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. The Lancet, Diabetes & Endocrinology. 2013;1:28-34.
18. Zhang W, Wang HD, Liu FC, Ye X, Tang WJ, Zhang PZ, Gu TW, Zhu DL, Bi Y. Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in patients with Newly Diagnosed Type 2 Diabetes. Diabetes Ther. 2021; https://doi.org/10.1007/s13300-021-01185-w.
19. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quiñones-Galvan A, Sironi AM, Natali A, Ferrannini E. Effect of Physiological Hyperinsulinemia on Gluconeogenesis in Nondiabetic Subjects and in Type 2 Diabetic Patients. Diabetes 2001;50:1807-12
20. Bertsch RA, Merchant MA. Study of the use of lipid panels as a marker of insulin resistance to determine cardiovascular risk. Perm J. 2015;19:4-10.
21. Pantoja-Torres B, Toro-Huamanchumo CJ, Urrunaga-Pastor D, Guarnizo-Poma M, Lazaro-Alcantara H, Paico-Palacios S, Ranilla-Seguin VDC, Benites-Zapata VA. High triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight healthy adults. Diabetes Metab Syndr Clin Res Rev. 2019;13:382-388.
22. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018; 98:2133–223.
23. Mary Sugden M, Holness M Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clinical Lipidology, 2011;6:4, 401-411, DOI: 10.2217/clp.11.32.
24. Stahel P, Xiao C, Nahmias A and Lewis GF. Role of the Gut in Diabetic Dyslipidemia. Front. Endocrinol. 2020;11:116. doi: 10.3389/fendo.2020.00116.
25. Sun Q, Li J, Gao F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J Diabetes. 2014;April 15; 5(2): 89-96.
26. Song Y, Ding W, Bei Y, Xiao Y, Tong HD, Wang LB, Ai LY. Insulin is a potential antioxidant for diabetes-associated cognitive decline via regulating Nrf2 dependent antioxidant enzymes. Biomed Pharmacother. 2018;Aug;104:474-484. doi: 10.1016/j.biopha.2018.04.097.
27. Rademaker D, de Wit L, Duijnhoven RG, Voormolen DN, Mol BW, Franx A, DeVries JH, Painter RC, van Rijn BB, SUGAR-DIP Study Group. Oral Glucose-Lowering Agent vs insulin for Gestational Diabetes: A Randomized Clinical Trial. JAMA 2024; doi:10.1001/jama.2024.23410.
28. Whitelaw DC, Kelly CA, Ironmonger W, Cunliffe C, New R, Phillips JN. Absorption of orally ingested insulin in human type 1 diabetic subjects: proof of concept study. Diabetes. 2005;54(suppl 1):5-LB.
29. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes, Obesity and Metabolism, 2013;15: 485–502.
30. Risovic I, Sumarac Dumanovic MS, Bojic M, Djekic D. Direct comparison two fixed‑ratio combination glucagon‑like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes. BMC Endocrine Disorders. 2023;23:28. https://doi.org/10.1186/s12902-023-01282-w.
31. Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, Pedersen SD, Buse JB. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS):a multicentre, randomised, phase 3b trial. The Lancet. 2023;402, Issue 10403P693-704August 26.
32. Eldor R, Kidron M, Greenberg-Shushlav Y, Arbit E. Novel Glucagon-Like Peptide-1 Analog Delivered Orally Reduces Postprandial Glucose Excursions in Porcine and Canine Models. J Diabetes Sci Technol. 2010;4(6):1516-1523